IOVA - ライオン・バイオテクノロジ―ズ (Iovance Biotherapeutics Inc.) ライオン・バイオテクノロジ―ズ

 IOVAのチャート


 IOVAの企業情報

symbol IOVA
会社名 Iovance Biotherapeutics Inc (ライオン・バイオテクノロジ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アイオワンス・バイオセラピューティクス(Iovance Biotherapeutics Inc.)(旧名:Lion Biotechnologies Inc)は臨床段階バイオ医薬品会社である。同社は患者自身の免疫システムによって癌細胞を根絶する癌免疫療法製品の開発・商業化に従事する。同社ののリードプログラムは転移性メラノーマの治療のために患者の腫瘍に由来するT細胞である腫瘍浸潤リンパ球を利用する養子細胞療法である。同社は子宮頸癌および頭頸部癌を治療するためにLN-145を開発中である。同社は眼科用メラノーマ、膀胱癌、乳癌、肺癌などの他の固形腫瘍適応症における非改変TILを評価するために国立癌研究所と共同研究を行う。同社はチェックポイントインヒビターKeytrudaと組み合わせてTILを評価するためにNCIと協力する。  ライオン・バイオテクノロジ―ズは米国のバイオ医薬品会社。転移性黒色腫、およびその他固形腫瘍に焦点を充てた新薬の開発に注力する。転移性黒色腫、およびその他固形腫瘍治療向けに、自家腫瘍浸潤リンパ球を使用した養子免疫療法の開発と商品化を手掛ける。本社はカリフォルニア州。   
本社所在地 999 Skyway Road Suite 150 San Carlos CA 94070 USA
代表者氏名 Iain D. Dukes イアン・D・デュークス
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 650-260-7120
設立年月日 39326
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 63人
url www.lionbio.com
nasdaq_url https://www.nasdaq.com/symbol/iova
adr_tso
EBITDA EBITDA(百万ドル) -105.72800
終値(lastsale) 10.92
時価総額(marketcap) 1043866485.48
時価総額 時価総額(百万ドル) 1134.795
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 858.70200
当期純利益 当期純利益(百万ドル) -105.17800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Iovance Biotherapeutics Inc revenues was not reported. Net loss increased 30% to $57.2M. Higher net loss reflects Research and development - Balancing val increase of 21% to $40.1M (expense) General_Administrative - Balancing val increase of 81% to $8.8M (expense) Stock-based Compensation in SGA increase of 50% to $4.9M (expense).

 IOVAのテクニカル分析


 IOVAのニュース

   Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25, 2021 - Stocks News Feed  2021/02/18 12:30:00 Stocks News Feed
SAN CARLOS, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021. Management will host a conference call and live audio webcast to discuss these results and… Read More »Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25, 2021
   Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Buy at $23, Sell at $47 - Live Trading News  2020/06/25 09:55:38 Live Trading News
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) $IOVA #Stocks #biopharmaceutical #MedicalStocks #Healthcarenews Buy at $23, Sell at $47 IOVA’s tumour infiltrating lymphocyte (TIL) therapy showed promising efficacy in metastatic melanoma Iovance BiotherapeuticsTicker: NASDAQ:IOVAPrice: $28.69Recommendation: Buy Sector News It is sad, but cancer is a pervasive illness that has affected 16% of the population of the world. In order […]
   Why Is Iovance Biotherapeutics (IOVA) Down 1.4% Since Last Earnings Report?  2020/06/04 15:31:26 Zacks Investment Research
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Iovance Biotherapeutics (IOVA) Upgraded to Buy: Here's What You Should Know  2020/06/02 16:00:12 Zacks Investment Research
Iovance Biotherapeutics (IOVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
   Iovance (IOVA) Q1 Loss Wider Than Expected, Revenues Nil  2020/05/06 15:26:00 Zacks Investment Research
Iovance's (IOVA) first-quarter loss wider than estimated. The company progressing well with its lead pipeline candidates.
   Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Buy at $23, Sell at $47 - Live Trading News  2020/06/25 09:55:38 Live Trading News
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) $IOVA #Stocks #biopharmaceutical #MedicalStocks #Healthcarenews Buy at $23, Sell at $47 IOVA’s tumour infiltrating lymphocyte (TIL) therapy showed promising efficacy in metastatic melanoma Iovance BiotherapeuticsTicker: NASDAQ:IOVAPrice: $28.69Recommendation: Buy Sector News It is sad, but cancer is a pervasive illness that has affected 16% of the population of the world. In order […]
   Why Is Iovance Biotherapeutics (IOVA) Down 1.4% Since Last Earnings Report?  2020/06/04 15:31:26 Zacks Investment Research
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Iovance Biotherapeutics (IOVA) Upgraded to Buy: Here's What You Should Know  2020/06/02 16:00:12 Zacks Investment Research
Iovance Biotherapeutics (IOVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
   Iovance (IOVA) Q1 Loss Wider Than Expected, Revenues Nil  2020/05/06 15:26:00 Zacks Investment Research
Iovance's (IOVA) first-quarter loss wider than estimated. The company progressing well with its lead pipeline candidates.
   Do Options Traders Know Something About Iovance Biotherapeutics (IOVA) Stock We Don't?  2020/04/17 12:43:00 Zacks Investment Research
Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.
   Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Buy at $23, Sell at $47 - Live Trading News  2020/06/25 09:55:38 Live Trading News
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) $IOVA #Stocks #biopharmaceutical #MedicalStocks #Healthcarenews Buy at $23, Sell at $47 IOVA’s tumour infiltrating lymphocyte (TIL) therapy showed promising efficacy in metastatic melanoma Iovance BiotherapeuticsTicker: NASDAQ:IOVAPrice: $28.69Recommendation: Buy Sector News It is sad, but cancer is a pervasive illness that has affected 16% of the population of the world. In order […]
   Why Is Iovance Biotherapeutics (IOVA) Down 1.4% Since Last Earnings Report?  2020/06/04 15:31:26 Zacks Investment Research
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Iovance Biotherapeutics (IOVA) Upgraded to Buy: Here's What You Should Know  2020/06/02 16:00:12 Zacks Investment Research
Iovance Biotherapeutics (IOVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
   Iovance (IOVA) Q1 Loss Wider Than Expected, Revenues Nil  2020/05/06 15:26:00 Zacks Investment Research
Iovance's (IOVA) first-quarter loss wider than estimated. The company progressing well with its lead pipeline candidates.
   Do Options Traders Know Something About Iovance Biotherapeutics (IOVA) Stock We Don't?  2020/04/17 12:43:00 Zacks Investment Research
Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ライオン・バイオテクノロジ―ズ IOVA Iovance Biotherapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)